Volociximab

Jump to: navigation, search
Volociximab
Monoclonal antibody
Type?
SourceTemplate:Infobox drug/mab source
Targeta5b1 integrin
Identifiers
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).

WikiDoc Resources for Volociximab

Articles

Most recent articles on Volociximab

Most cited articles on Volociximab

Review articles on Volociximab

Articles on Volociximab in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Volociximab

Images of Volociximab

Photos of Volociximab

Podcasts & MP3s on Volociximab

Videos on Volociximab

Evidence Based Medicine

Cochrane Collaboration on Volociximab

Bandolier on Volociximab

TRIP on Volociximab

Clinical Trials

Ongoing Trials on Volociximab at Clinical Trials.gov

Trial results on Volociximab

Clinical Trials on Volociximab at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Volociximab

NICE Guidance on Volociximab

NHS PRODIGY Guidance

FDA on Volociximab

CDC on Volociximab

Books

Books on Volociximab

News

Volociximab in the news

Be alerted to news on Volociximab

News trends on Volociximab

Commentary

Blogs on Volociximab

Definitions

Definitions of Volociximab

Patient Resources / Community

Patient resources on Volociximab

Discussion groups on Volociximab

Patient Handouts on Volociximab

Directions to Hospitals Treating Volociximab

Risk calculators and risk factors for Volociximab

Healthcare Provider Resources

Symptoms of Volociximab

Causes & Risk Factors for Volociximab

Diagnostic studies for Volociximab

Treatment of Volociximab

Continuing Medical Education (CME)

CME Programs on Volociximab

International

Volociximab en Espanol

Volociximab en Francais

Business

Volociximab in the Marketplace

Patents on Volociximab

Experimental / Informatics

List of terms related to Volociximab


Overview

Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.

External link



Linked-in.jpg